Evidence map›Paper›PMID 42268525›Full record

ArticleDiscover oncology2026

The prognostic and immunological role of NADPH oxidase in early and locally advanced lung adenocarcinoma.

Jingjing Deng, Linfeng Cao, Gouxin Hou, Xiaolong Ma

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Jingjing DengDepartment of Critical Care Medicine, the Key Clinical Specialties of Jiangsu Province, Yixing People's Hospital, The Affiliated Yixing Hospital of Jiangsu University, Yixing Branch of Wuxi Medical Center of Nanjing Medical University, The Affiliated Yixing Clinical School of Medical School of Yangzhou University, No.1588 Xincheng Road, Yixing, 214200, Jiangsu, China. djj910625@163.com.
Linfeng CaoDepartment of Pulmonary and Critical Care Medicine, The First Hospital of Jiaxing, Affiliated Hospital of Jiaxing University, No. 1882 Zhonghuan South Road, Jiaxing, 314000, Zhejiang, P.R. China.
Gouxin HouDepartment of Oncology, The First Hospital of Jiaxing, Affiliated Hospital of Jiaxing University, Jiaxing, China.
Xiaolong MaDepartment of Pulmonary and Critical Care Medicine, The First Hospital of Jiaxing, Affiliated Hospital of Jiaxing University, No. 1882 Zhonghuan South Road, Jiaxing, 314000, Zhejiang, P.R. China. maxiaolong801005@sina.com.

Funding

the Key Discipline of Jiaxing Respiratory Medicine Construction Project No.2019-zc-04
6 · The paper itself

Abstract

Lung adenocarcinoma (LUAD) is the pathological type with the highest proportion and heterogeneity in lung cancer. NADPH oxidase is an important enzyme in the biological respiratory chain that plays a decisive role in cell growth, regulation, and apoptosis, which translating seven gene families, namely NOX1-5 and DUOX1-2. The current study aimed to investigate the expression, and prognostic and immune-related roles of this gene family in early and advanced LUAD. Gene expression was examined using the Oncomine™ database, prognostic value was analyzed by Kaplan-Meier analysis, expression of NOX2 and NOX4 in early and locally advanced LUAD was validated using RT-qPCR, and the correlation of infiltrating immune cells was validated by tumor immune estimation resources (TIMER). Over-expressed NOX4 was associated with lower prognosis; NOX2 was found to be under-expressed in LUAD. Both NOX2 and NOX4 expression was positively related to tumor purity and had positive correlation with infiltrating levels of immune cells in TIMER. The data reflected the potential association of NADPH oxidase in early and locally advanced lung adenocarcinoma. Our data suggested that the combination of NOX4 suppression, NOX2 depression, and immunotherapy would improve clinical outcome in these tumors.

Identifiers

PMID42268525
PMCPMC13478044

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.